Glimepirid
Klassificering: BATC kod: A10BB12
Sammanfattning
Det saknas analyser om skillnader mellan könen i kontrollerade studier avseende effekt av glimepirid. Farmakokinetiskt finns dock ingen påvisad könsskillnad.
Allmänt indikerar vissa studier att kvinnor har högre risk att få hypoglykemi vid antidiabetikabehandling än män.
Additional information
Pharmacokinetics and dosing
Population pharmacokinetic analyses have found no sex differences in the pharmacokinetics of glimepiride after adjustment for body weight [3, 4]. No studies with a clinically relevant sex analysis regarding the dosing of glimepiride have been found.
Effects
No studies with a clinically relevant sex analysis regarding the effects of glimepiride have been found.
Adverse effects
The ACCORD study (Action to Control Cardiovascular Risk in Diabetes) was a randomized, controlled trial designed to test the effect of intensive glucose control compared with standard control on cardiovascular outcomes in patients with type 2 diabetes. The study showed that women had a higher risk of hypoglycemia than men regardless of treatment in general [1].
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Other information
An observational retrospective study compared the effects of glimepiride or glibenclamide treatment on body weight over 12 months of treatment in patients with type 2 diabetes. Patient's sex had no significant influence on change in body weight or BMI [2].
Försäljning på recept
Fler män än kvinnor hämtade ut tabletter innehållande glimepirid (ATC-kod A10BB12) på recept i Sverige år 2019, totalt 11 538 män och 7 155 kvinnor. Det motsvarar 2,2 respektive 1,4 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 70-84 år hos båda könen. I genomsnitt var tabletter innehållande glimepirid 1,7 gånger vanligare hos män [5]. Detta speglar könsskillnaden i prevalens av typ 2-diabetes [6].
Uppdaterat: 2020-10-06
Litteratursökningsdatum: 2020-07-09
Referenser
- Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;340:b5444. PubMed
- Martin S, Kolb H, Beuth J, van Leendert R, Schneider B, Scherbaum WA. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Diabetologia. 2003;46:1611-7. PubMed
- Karim A, Zhao Z, Slater M, Bradford D, Schuster J, Laurent A. Replicate study design in bioequivalency assessment, pros and cons: bioavailabilities of the antidiabetic drugs pioglitazone and glimepiride present in a fixed-dose combination formulation. J Clin Pharmacol. 2007;47:806-16. PubMed
- AMARYL (glimepirid). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2018-12-01, cited 2020-07-09].
- Jansson SP, Fall K, Brus O, Magnuson A, Wändell P, Östgren CJ et al. Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden. Diabet Med. 2015;32(10):1319-28. PubMed
Faktagranskat av: Carl-Olav Stiller
Godkänt av: Karin Schenck-Gustafsson